• Oct 26, 2026

  $172.06+0.33%

• Oct 23, 2026

  $171.49-0.63%

• Oct 22, 2026

  $172.57+2.45%

  The shares rose 2.45% on the session while the broad-market S&P 500 ETF (SPY) moved -1.18% [1]. The move was therefore not shared by the broad market, which fell as this stock rose [1]. None of the other items reported anything about the company itself.

  • 1Broad market

• Oct 21, 2026

  $168.45-0.22%

• Oct 20, 2026

  $168.82+2.97%

  Shares rose 2.97% on a day when Seeking Alpha reported that Amgen and AstraZeneca released phase 3 results for Tezspire in eosinophilic esophagitis, with the CROSSING trial hitting histologic remission and reducing dysphagia [1]. Seeking Alpha also reported an AI collaboration between AstraZeneca and Oracle to speed up clinical trials [2]. The broad market, via the S&P 500 ETF, moved only +0.34%, so the move was largely not shared by the broad market [3]. Volume was 1.7x the trailing 20-session average [4].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Broad market
  • 4Market data

• Oct 19, 2026

  $163.95-0.88%

• Oct 16, 2026

  $165.41-0.76%

Closing prices for AZN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.